Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report

Autor: Piero Sismondi, Nicoletta Biglia, M.Gina Lanza, Carlo Campagnoli, Clementina Peris, L. Lesca
Rok vydání: 1994
Předmět:
Adult
medicine.medical_specialty
Norethisterone
medicine.drug_class
medicine.medical_treatment
Administration
Oral
Breast Neoplasms
Dydrogesterone
Administration
Cutaneous
Hormone replacement treatment
General Biochemistry
Genetics and Molecular Biology
Insulin-like growth factor
Sex hormone-binding globulin
Risk Factors
Internal medicine
Sex Hormone-Binding Globulin
medicine
Humans
Insulin-Like Growth Factor I
Progestogens
Climacteric
Estrogens
Conjugated (USP)
Progestogen
biology
Estradiol
business.industry
Estrogen Replacement Therapy
Obstetrics and Gynecology
Middle Aged
medicine.disease
Insulin-like growth factor I
Sex hormone binding globulin
Breast cancer risk
Norethisterone acetate
Menopause
Norethindrone Acetate
Endocrinology
Estrogen
biology.protein
Drug Therapy
Combination
Female
Norethindrone
business
hormones
hormone substitutes
and hormone antagonists
medicine.drug
Zdroj: Maturitas. 19(1)
ISSN: 0378-5122
Popis: Oral oestrogen treatment in postmenopausal women causes a decrease of insulin-like growth factor I (IGF-I) serum level, probably through a hepatocellular effect. To explore the possibility that the androgenic progestogens oppose this effect, serum IGF-I and sex hormone binding globulin (SHBG) were evaluated in two groups of patients treated respectively with oral conjugated oestrogens (oCE) or transdermal oestradiol (tdE2), in a first phase with the addition of dydrogesterone (DYDR), a non-androgenic progestogen, and subsequently with the addition of norethisterone acetate (NETA). With respect to basal values, treatment with oCE+DYDR caused an increase of SHBG (P < 0.002) and a decrease of IGF-I serum levels (P < 0.05); the shift to NETA addition opposed both effects: SHBG levels decreased partially but significantly (P < 0.01 vs. oCE + DYDR) and IGF-I returned to basal values with a significant increase with respect to the oCE + DYDR phase (P < 0.02). No changes were observed in the tdE2 + DYDR treated women; in this group the shift to NETA addition caused a significant decrease of SHBG values (P < 0.001 vs. before treatment and vs. tdE2 + DYDR phase) and a slight increase of IGF-I values. These differential effects on IGF-I and SHBG serum levels might be relevant as far as breast cancer risk is concerned.
Databáze: OpenAIRE
Externí odkaz: